Analytical and Pharmacokinetics Core

核心1：分析和药代动力学核心 派：威廉·赞博尼，制药公司。威廉·赞博尼博士是埃谢尔曼药学院的副教授。他是北卡罗来纳大学实验治疗中心GLP分析设施的主任和转化肿瘤学和纳米药物开发研究所(T0ND2I)实验室的主任。几年来，他一直从事抗癌药物的翻译研究。他的研究兴趣集中在 药代动力学、药效学和药物遗传学原理在癌症化疗优化中的应用。他还在开发纳米颗粒和纳米抗癌药物，并评估这些药物的处置与网状内皮系统之间的关系。作为这些研究的一部分，他使用微透析来评估肿瘤细胞外液的处置。 抗癌剂的种类和影响抗癌剂输送和移除的因素。他还开发了区分药物的非活性胶囊和活性释放形式的方法和技术，并正在从纳米颗粒和纳米颗粒的药代动力学和药效配置来评估潜在的表型探针。研究的临床相关性被强调为需要用抗癌剂治疗实体肿瘤，这些抗癌剂具有高肿瘤脂质体和纳米粒制剂的递送能力，并产生给药时间表以增强肿瘤的选择性摄取。

Core 1: Analytical and Pharmacokinetics Core PI: William Zamboni, Pharm. D., Ph.D. William Zamboni is an Associate Professor in the Eshelman School of Pharmacy. He is the Director of GLP Analytical Facility, Center for Experimental Therapeufics and the Director of the Translational Oncology and Nanoparticle Drug Development Inifiafive (T0ND2I) Lab at UNC. He has been involved in translational studies of anticancer agents for several years. His research interests focus on the application of pharmacokinetic, pharmacodynamic, and pharmacogenetic principles in the optimizafion of the chemotherapeufic treatment of cancer. He is also developing nanosomal and nanoparticle anticancer agents and evaluating the relafionship between the disposition of these agents and the reticuloendothelial system. As part of these studies, he has used microdialysis to evaluate the tumor extracellular fluid disposition of anticancer agents and factors affecting the delivery and removal of anticancer agents. He has also developed methods and technologies to differentiate between the inactive-encapsulate and active-release forms of the drugs and are evaluafing potential phenotypic probes from the pharmacokinetic and pharmacodynamic disposition of nanosomal and nanoparticles. The clinical relevance of studies is underscored by the need to treat solid tumors with anticancer agents that have a high tumor delivery of liposomal and nanoparticle agents, and generate administration schedules to enhance selective tumor uptake.